联环药业：公司坚持围绕主业推进并购，遵循“不偏离主业、形成协同效应”的核心逻辑

Core Viewpoint - The company emphasizes its commitment to core business operations and strategic acquisitions, aiming for synergy and collaboration with high-quality targets in the future [1] Group 1: Business Strategy - The company will continue to pursue mergers and acquisitions that align with its core business and create synergistic effects [1] - There is no current plan for a Hong Kong stock listing, but the company will evaluate this based on business development and market conditions [1] Group 2: Financial Position - The company's financial situation is manageable, supporting existing research and business needs [1] - If the funding requirements for innovative drug projects increase in the later stages, the company may consider refinancing options [1] Group 3: Stock Market Operations - The company has been included in the Shanghai-Hong Kong Stock Connect, which will help optimize its equity structure and enhance stock liquidity [1]